SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced that it will make any new features
approved for the t:slim X2™ Insulin Pump by the U.S. Food and Drug
Administration (FDA) in 2018 available to all in-warranty users at no
cost through the Tandem Device Updater.1 Tandem and
continuous glucose monitoring partner, Dexcom, Inc., also announced the
extension of their existing joint welcome program for Animas customers
from December 31, 2017 to March 31, 2018, matching the expiration date
of Dexcom's program to that of Tandem's Touch Simplicity Today pump
"Our commitment to offer t:slim X2 customers all new functionality
approved by the FDA in 2018 for no additional cost underscores our goal
to simplify the lives of people with diabetes by using software updates,
rather than hardware replacements, to provide rapid access to new
innovations," said Kim Blickenstaff, president and CEO of Tandem
Diabetes Care. "The tools necessary for diabetes management can be
costly, and today's announcement is evidence of our vision to use
technology to remove a major barrier that may delay people from
receiving all of the potential benefits of pump therapy through access
to the latest available features."
Tandem is the only company with a tool for providing remote software
updates for its insulin pumps as new features are approved by the FDA.
The Company successfully demonstrated its market-differentiating Tandem
Device Updater by providing CGM integration to thousands of t:slim X2
customers for no cost following the FDA's approval of the t:slim X2
Insulin Pump with Dexcom G5 Mobile CGM integration in August 2017. 2
t:slim X2 Pump users were able to update their pumps from home using
their personal computer. Any new features approved by the FDA for the
t:slim X2 Pump in 2018 will be made available to all in-warranty t:slim
X2 Pump users at no cost through the Tandem Device Updater.
Tandem and Dexcom Expand Existing Welcome Offers for Animas Customers
Tandem and Dexcom are now extending the terms of their welcome programs
for Animas customers through March 31, 2018, to allow more Animas users
access to the only CGM-integrated insulin pump approved to make
treatment decisions without fingersticks.3
Dexcom Extends Existing t:slim X2 Welcome Program
to March 31, 2018
Animas customers who purchase a t:slim X2 Insulin Pump can get started
with a new Dexcom G5 Mobile CGM and receive a $200 reward card for
taking a patient survey. The eligibility period for this program has
been extended for Tandem customers from late 2017 to March 31, 2018.
"We are excited to be able to extend this program so that more Animas
customers who are considering a t:slim X2 Pump can take advantage of
this opportunity to start on a new Dexcom G5 Mobile CGM system at the
same time," said Steve Pacelli, Executive Vice President of Strategy and
Corporate Development at Dexcom. "Tandem's t:slim X2 Pump is now the
only pump that integrates with our G5 Mobile CGM, and is a great option
for Animas customers who chose their pumps for Dexcom integration. We
hope this program extension helps make things easier for these Animas
customers who are currently weighing their available pump options."
Tandem's Touch Simplicity Today Pump Access
Program for Animas Customers
For a limited time, Animas pump users with warranties expiring on or
before September 30, 2019 can use a Tandem insulin pump for the
remainder of their warranty. The offer can be used for up to 24 months,
for a refundable deposit of $999, which can be applied to the purchase
of a new Tandem pump and/or supplies at the end of their current Animas
warranty. The customer can choose to return the pump in the first 60
days of the program for a full refund of their deposit, or during the
first nine months for a pro-rated refund based on the length of time
they were in possession of the pump. This offer is available to eligible
Animas customers through March 31, 2018.
"We believe the t:slim X2 Pump with Dexcom G5 Mobile CGM integration
offers the simplest, most comfortable transition option for Animas
customers, particularly for those who have only ever used an Animas
pump," said Mr. Blickenstaff. "Not only is the t:slim X2 Pump approved
for use by children as young as six years old, it is also the only pump
that is integrated with the CGM brand Animas users already know and
love, which allows for CGM data to be shared with loved ones and
caregivers via a mobile device.4"
Additional information on Tandem and Dexcom welcome programs available
for Animas customers can be found at www.tandemdiabetes.com/animas.
About the t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration
The t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose
monitoring (CGM) integration is the first sensor-augmented insulin pump
approved to let users make treatment decisions without pricking their
finger.3 It is the only available pump that conveniently
displays a user's insulin delivery activity and Dexcom G5 Mobile CGM
data together on a single device. It is also the only insulin pump
capable of remote software updates, allowing existing users to add
features like CGM integration from home. It is up to 38% smaller than
other pumps, but includes advanced features like a large color
touchscreen, Bluetooth® radio, rechargeable battery, USB connectivity,
and a 300-unit insulin capacity.
For additional product and safety information, visit www.tandemdiabetes.com/tslimX2info
or call (877) 801-6901, Monday - Friday between 6am and 5pm Pacific Time
Free t:slim X2 Pump Demo on Your Mobile Device
Download Tandem's free t:simulator™ App to experience the touchscreen
interface of the t:slim X2 Pump with Dexcom G5 Mobile CGM integration
directly on your mobile device. For more information and to download the
app, visit http://www.tandemdiabetes.com/tsimulator.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem manufactures and sells the t:slim
X2™ Insulin Pump, the only pump capable of remote feature updates using
a personal computer, and the t:flex® Insulin Pump, the first pump
designed for people with greater insulin requirements. Tandem is based
in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on
Facebook at www.facebook.com/TandemDiabetes.
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care and t:flex are registered trademarks, and t:slim X2
and t:simulator are trademarks of Tandem Diabetes Care, Inc. Dexcom and
Dexcom G5 are registered trademarks of Dexcom, Inc. All other trademarks
are the property of their respective owners.
Forward Looking Statement
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the Company's plans to make any new t:slim
X2 Pump feature releases approved by the U.S. Food and Drug
Administration (FDA) in 2018 available to all in-warranty users at no
cost through the Tandem Device Updater, the Company's plan to offer the
Touch Simplicity Today Pump Access Program and Dexcom's continued offer
of a welcome program to new t:slim X2 customers. The Company's actual
results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including the Company's ability to complete the development and obtain
required FDA approvals to offer future feature releases using the Tandem
Device Updater and the Company's inability to influence Dexcom's
administration of the welcome program to new t:slim X2 customers. Other
risks and uncertainties are identified in the Company's most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other
documents that the Company files with the Securities and Exchange
Commission. Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. Tandem undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
1 Additional feature
updates are not currently available for the t:slim X2 Pump with Dexcom
G5 CGM integration and are subject to future FDA approvals. A
prescription and additional training may be required to access certain
future software updates. Offer only available to customers in the United
2 Dexcom G5 Mobile CGM sold separately. CGM
coverage may vary based on insurance. Please consult your CGM supplier
for coverage information. The Dexcom G5 Mobile CGM transmitter can only
be paired with one medical device (either a Dexcom receiver or t:slim X2
Pump) and one consumer device (phone or tablet) at the same time.
CGM-based treatment requires fingersticks for calibration; may result in
hypoglycemia if calibration not performed, when taking acetaminophen, or
if symptoms/expectations do not match CGM readings.
Following your shared data requires the Dexcom Follow app.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171024006695/en/
Tandem Diabetes Care, Inc.
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media